Foundations Investment Advisors LLC Buys 3,292 Shares of Amgen Inc. $AMGN

Key Points

• Foundations Investment Advisors LLC increased its Amgen stake by 8.4% in the fourth quarter, buying 3,292 additional shares and bringing its total holding to 42,354 shares worth about $13.86 million.
• Amgen reported stronger-than-expected quarterly results, with EPS of $5.15 versus the $4.77 consensus and revenue of $8.62 billion, up 5.8% year over year. The company also reiterated FY 2026 EPS guidance of 21.7 to 23.1.
• Wall Street remains cautious overall: analysts have a consensus “Hold” rating on AMGN, with an average price target of $355.19. Amgen also announced a quarterly dividend of $2.52 per share, yielding about 3.0% annually.

Foundations Investment Advisors LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 42,354 shares of the medical research company's stock after purchasing an additional 3,292 shares during the period. Foundations Investment Advisors LLC's holdings in Amgen were worth $13,863,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Anfield Capital Management LLC boosted its holdings in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock valued at $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC boosted its holdings in shares of Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Board of the Pension Protection Fund bought a new position in shares of Amgen during the 4th quarter valued at about $26,000. Manning & Napier Advisors LLC boosted its holdings in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC bought a new position in shares of Amgen during the 4th quarter valued at about $33,000. Institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Rothschild & Co Redburn increased their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a "sell" rating in a report on Wednesday, February 18th. Leerink Partners reaffirmed a "market perform" rating and issued a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. Wells Fargo & Company increased their price target on shares of Amgen from $375.00 to $390.00 and gave the company an "equal weight" rating in a report on Thursday, March 19th. UBS Group lifted their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, April 13th. Finally, Daiwa Securities Group dropped their price objective on shares of Amgen from $410.00 to $390.00 and set an "outperform" rating for the company in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $355.19.

Amgen Stock Performance

Amgen stock opened at $336.06 on Thursday. The company has a 50 day moving average price of $343.32 and a 200-day moving average price of $345.27. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The company has a market capitalization of $181.37 billion, a PE ratio of 23.39, a P/E/G ratio of 3.37 and a beta of 0.44.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the firm posted $4.90 earnings per share. Amgen's revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts forecast that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. Amgen's payout ratio is 70.15%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company's stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is owned by company insiders.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.